CONTEXT: Somatrogon is a long-acting recombinant human growth hormone treatment developed as a once-weekly treatment for pediatric patients with growth hormone deficiency (GHD). OBJECTIVE: Evaluate patient and caregiver perceptions of the treatment burden associated with the once-weekly somatrogon injection regimen vs a once-daily Somatropin injection regimen. METHODS: Pediatric patients (≥3 to <18 years) with GHD receiving once-daily somatropin at enrollment were randomized 1:1 to Sequence 1 (12 weeks of once-daily Somatropin, then 12 weeks of once-weekly somatrogon) or Sequence 2 (12 weeks of once-weekly somatrogon, then 12 weeks of once-daily Somatropin). Treatment burden was assessed using validated questionnaires completed by patients and caregivers. The primary endpoint was the difference in mean overall life interference (LI) total scores after each 12-week treatment period (somatrogon vs Somatropin), as assessed by questionnaires. RESULTS: Of 87 patients randomized to Sequence 1 (n = 43) or 2 (n = 44), 85 completed the study. Once-weekly somatrogon had a significantly lower treatment burden than once-daily Somatropin, based on mean overall LI total scores after somatrogon (8.63) vs Somatropin (24.13) treatment (mean difference -15.49; 2-sided 95% CI -19.71, -11.27; P < .0001). Once-weekly somatrogon was associated with greater convenience, higher satisfaction with treatment experience, and less LI. The incidence of treatment-emergent adverse events (TEAEs) for Somatropin and somatrogon was 44.2% and 54.0%, respectively. No severe or serious AEs were reported. CONCLUSION: In pediatric patients with GHD, once-weekly somatrogon had a lower treatment burden and was associated with a more favorable treatment experience than once-daily Somatropin.

Children's Faculty Hospital Košice Košice Slovakia

Department of Pediatrics 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Nemours Children's Health Jacksonville FL 32207 USA

Nemours Children's Hospital Orlando FL 32827 USA

Pfizer Inc Collegeville PA 19426 USA

Pfizer Inc New York NY 10017 USA

Pfizer Ltd Tadworth UK

Rocky Mountain Pediatric Endocrinology Centennial CO 80112 USA

Sutter Medical Center and Center of Excellence in Diabetes and Endocrinology Sacramento CA 95821 USA

UCL Great Ormond Street Institute of Child Health London UK

UMHAT St Marina Varna Bulgaria

See more in PubMed

Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab. 1958;18(8):901-903. PubMed

Reh CS, Geffner ME. Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review. Clin Pharmacol. 2010;2:111-122 PubMed PMC

Albertsson-Wikland K, Westphal O, Westgren U. Daily subcutaneous administration of human growth hormone in growth hormone deficient children. Acta Paediatr Scand. 1986;75(1):89-97. PubMed

Ranke MB. Clinical experience with authentic recombinant human growth hormone. Acta Paediatr Scand Suppl. 1986;75(s325):90-92. PubMed

Takano K, Shizume K, Hibi I, et al. . Clinical trial with authentic recombinant somatropin in Japan. Acta Paediatr Scand Suppl. 1987;76(s331):18-24. PubMed

Cutfield WS, Derraik JGB, Gunn AJ, et al. . Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS One. 2011;6(1):e16223-e16223. PubMed PMC

Kapoor RR, Burke SA, Sparrow SE, et al. . Monitoring of concordance in growth hormone therapy. Arch Dis Child. 2008;93(2):147-148. PubMed

Miller BS, Velazquez E, Yuen KCJ. Long-acting growth hormone preparations - current status and future considerations. J Clin Endocrinol Metab. 2020;105(6):e2121-e2133. PubMed PMC

Graham S, Weinman J, Auyeung V. Identifying potentially modifiable factors associated with treatment non-adherence in paediatric growth hormone deficiency: a systematic review. Horm Res Paediatr. 2018;90(4):221-227. PubMed

Brod M, Hojbjerre L, Alolga SL, Beck JF, Wilkinson L, Rasmussen MH. Understanding treatment burden for children treated for growth hormone deficiency. Patient. 2017;10(5):653-666. PubMed PMC

Kremidas D, Wisniewski T, Divino VM, et al. . Administration burden associated with recombinant human growth hormone treatment: perspectives of patients and caregivers. J Pediatr Nurs. 2013;28(1):55-63. PubMed

McNamara M, Turner-Bowker DM, Westhead H, et al. . Factors driving patient preferences for growth hormone deficiency (GHD) injection regimen and injection device features: a discrete choice experiment. Patient Prefer Adherence. 2020;2020(14):781-793. PubMed PMC

Turner-Bowker DM, Yaworsky A, Palladino A, et al. . Development and psychometric evaluation of the Life Interference Questionnaire for Growth Hormone Deficiency (LIQ-GHD) to assess growth hormone injection burden in children and adults. Patient. 2020;13(3):289-306. PubMed PMC

Hershkovitz O, Bar-Ilan A, Guy R, et al. . In vitro and in vivo characterization of MOD-4023, a long-acting carboxy-terminal peptide (CTP)-modified human growth hormone. Mol Pharm. 2016;13(2):631-639. PubMed

Zelinska N, Iotova V, Skorodok J, et al. . Long-acting C-terminal peptide–modified hGH (MOD-4023): results of a safety and dose-finding study in GHD children. J Clin Endocrinol Metab. 2017;102(5):1578-1587. PubMed

Deal C, Steelman J, Vlachopapadopoulou E, et al. . Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study. J Clin Endocrinol Metab. 2022;107(7):e2717-e2728. Doi: 10.1210/clinem/dgac220 PubMed DOI PMC

Graham S, Auyeung V, Weinman J. Exploring potentially modifiable factors that influence treatment non-adherence amongst pediatric growth hormone deficiency: a qualitative study. Patient Prefer Adherence. 2020;14:1889-1899. PubMed PMC

Tanaka T, Sato T, Yuasa A, Akiyama T, Tawseef A. Patient preferences for growth hormone treatment in Japanese children. Pediatr Int. 2021;63:1185-1191. Doi: 10.1111/ped.14760 PubMed DOI PMC

Hughes IP, Choong C, Rath S, et al. . Early cessation and non-response are important and possibly related problems in growth hormone therapy: an OZGROW analysis. Growth Horm IGF Res. 2016;29:63-70. PubMed

Wit JM, Deeb A, Bin-Abbas B, Al Mutair A, Koledova E, Savage MO. Achieving optimal short- and long-term responses to paediatric growth hormone therapy. J Clin Res Pediatr Endocrinol. 2019;11(4):329-340. PubMed PMC

Qiao Q, Ouwens MJ, Grandy S, Johnsson K, Kostev K. Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany. Diabetes Metab Syndr Obes. 2016;(9):201-205. PubMed PMC

Cutter G, Veneziano A, Grinspan A, et al. . Higher satisfaction and adherence with glatiramer acetate 40mg/mL TIW vs 20mg/mL QD in RRMS. Mult Scler Relat Disord. 2019;33:13-21. PubMed

Cutter G, Veneziano A, Grinspan A, et al. . Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD. Mult Scler Relat Disord. 2020;40:101957. PubMed

Loftus J, Yaworsky A, Roland C, et al. . Systematic review of patient experience with a less frequent injection schedule for growth hormone deficiency. JMCP. 2021;27(4-a Suppl).

Hoos A, Anderson J, Boutin M, et al. . Partnering with patients in the development and lifecycle of medicines: a call for action. Ther Innov Regul Sci. 2015;49(6):929-939. PubMed PMC

Yeoman G, Furlong P, Seres M, et al. . Defining patient centricity with patients for patients and caregivers: a collaborative endeavour. BMJ Innov. 2017;3(2):76-83. PubMed PMC

Hey-Hadavi J, Pleil A, Deeb LC, et al. . Ease of use and preference for a new disposable self-injection pen compared with a reusable pen for administering recombinant human growth hormone: a multicenter, 2-Month, single-arm, open-label clinical trial in patient-caregiver dyads. Clin Ther. 2010;32(12):2036-2047. PubMed

Grimberg A, Lindberg A, Wajnrajch M, Cucchiara AJ, Camacho-Hubner C. Racial/ethnic disparities in US pediatric growth hormone treatment. Horm Res Paediatr. 2018;90(2):102-108. PubMed PMC

Ranke MB, Lindberg A, Tanaka T, Camacho-Hubner C, Dunger DB, Geffner ME. Baseline characteristics and gender differences in prepubertal children treated with growth hormone in Europe, USA, and Japan: 25 Years’ KIGS(R) experience (1987-2012) and review. Horm Res Paediatr. 2017;87(1):30-41. PubMed